| scholarly article | Q13442814 |
| P2093 | author name string | Bingliang Fang | |
| P2860 | cites work | Reactive oxygen generated by Nox1 triggers the angiogenic switch | Q24292207 |
| PTP1B regulates leptin signal transduction in vivo | Q24294879 | ||
| Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor | Q24305821 | ||
| A new protein containing an SH2 domain that inhibits JAK kinases | Q24313242 | ||
| Tyrosines 1148 and 1173 of activated human epidermal growth factor receptors are binding sites of Shc in intact cells | Q24314518 | ||
| The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling | Q24337017 | ||
| A Drosophila PIAS homologue negatively regulates stat92E | Q24555776 | ||
| EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib | Q24561953 | ||
| A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors | Q24568224 | ||
| A comprehensive catalogue of somatic mutations from a human cancer genome | Q24628532 | ||
| Activation of signal transducer and activator of transcription 3 through a phosphomimetic serine 727 promotes prostate tumorigenesis independent of tyrosine 705 phosphorylation | Q24632832 | ||
| STAT3 Serine Phosphorylation by ERK-Dependent and -Independent Pathways Negatively Modulates Its Tyrosine Phosphorylation | Q24644334 | ||
| A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene | Q24647664 | ||
| Somatic mutations affect key pathways in lung adenocarcinoma | Q24648102 | ||
| An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation | Q24650225 | ||
| Suppression of non-small cell lung tumor development by the let-7 microRNA family | Q24651985 | ||
| Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas | Q24669579 | ||
| Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality | Q24685515 | ||
| Intermittent preventive therapy for malaria during pregnancy using 2 vs 3 or more doses of sulfadoxine-pyrimethamine and risk of low birth weight in Africa: systematic review and meta-analysis | Q26849714 | ||
| Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma | Q27629132 | ||
| Oxidation state of the active-site cysteine in protein tyrosine phosphatase 1B | Q27641431 | ||
| EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy | Q27824812 | ||
| The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies | Q27851393 | ||
| Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. | Q27851397 | ||
| Free Radicals in the Physiological Control of Cell Function | Q27860480 | ||
| RAS is regulated by the let-7 microRNA family | Q27860522 | ||
| Mammalian Ras interacts directly with the serine/threonine kinase Raf | Q27860833 | ||
| Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins | Q27860890 | ||
| Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib | Q27861059 | ||
| Regulation of STAT3 by direct binding to the Rac1 GTPase | Q28140511 | ||
| Serine phosphorylation and negative regulation of Stat3 by JNK | Q28145918 | ||
| Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals | Q28236222 | ||
| Activation of STAT3 is a marker of poor prognosis in human colorectal cancer | Q28239264 | ||
| Specific Inhibition of Stat3 Signal Transduction by PIAS3 | Q28255665 | ||
| Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer | Q28267996 | ||
| The concept of synthetic lethality in the context of anticancer therapy | Q28268061 | ||
| Complexes of Ras.GTP with Raf-1 and mitogen-activated protein kinase kinase | Q28269621 | ||
| Jak2 is essential for signaling through a variety of cytokine receptors | Q28270987 | ||
| GAP control: regulating the regulators of small GTPases | Q28271241 | ||
| Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells | Q28277030 | ||
| Phosphotyrosine 1173 Mediates Binding of the Protein-tyrosine Phosphatase SHP-1 to the Epidermal Growth Factor Receptor and Attenuation of Receptor Signaling | Q28282019 | ||
| Grb2/Ash binds directly to tyrosines 1068 and 1086 and indirectly to tyrosine 1148 of activated human epidermal growth factor receptors in intact cells | Q28287096 | ||
| Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells | Q28288970 | ||
| Oncogenically active MYD88 mutations in human lymphoma | Q28301648 | ||
| Oxidative stress in NSC-741909-induced apoptosis of cancer cells | Q33863911 | ||
| Cooperative transcriptional activity of Jun and Stat3 beta, a short form of Stat3 | Q33884748 | ||
| Rac1 mediates STAT3 activation by autocrine IL-6 | Q33929488 | ||
| Signaling from Ras to Rac and beyond: not just a matter of GEFs | Q33931717 | ||
| A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells | Q33935165 | ||
| Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. | Q33936548 | ||
| Distinct mechanisms of activation of Stat1 and Stat3 by platelet-derived growth factor receptor in a cell-free system | Q33958130 | ||
| Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways | Q33984585 | ||
| STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells | Q34052726 | ||
| Ras and Rho GTPases: a family reunion | Q34073399 | ||
| Use of isogenic human cancer cells for high-throughput screening and drug discovery | Q34093306 | ||
| Antitumor Activity of a Novel Oncrasin Analogue Is Mediated by JNK Activation and STAT3 Inhibition | Q34103117 | ||
| Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer | Q34109397 | ||
| Activation of STAT proteins and growth control | Q34136104 | ||
| Synthetic lethal screen of an EGFR-centered network to improve targeted therapies. | Q34175680 | ||
| WT1: a weak spot in KRAS-induced transformation | Q34245506 | ||
| Antagonistic effect of flavonoids on NSC-741909-mediated antitumor activity via scavenging of reactive oxygen species | Q34259118 | ||
| Stat3 dimerization regulated by reversible acetylation of a single lysine residue | Q34384817 | ||
| Reactive oxygen species are downstream mediators of p53-dependent apoptosis | Q34403292 | ||
| Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study | Q34411696 | ||
| Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts | Q34418354 | ||
| Thioredoxin-like 2 regulates human cancer cell growth and metastasis via redox homeostasis and NF-κB signaling | Q34428947 | ||
| TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. | Q34436986 | ||
| Hydrogen Peroxide: A Key Messenger That Modulates Protein Phosphorylation Through Cysteine Oxidation | Q34467727 | ||
| Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. | Q34536780 | ||
| Essential role of STAT3 in postnatal survival and growth revealed by mice lacking STAT3 serine 727 phosphorylation | Q34550563 | ||
| Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer | Q34557318 | ||
| Expression of AFP and STAT3 Is Involved in Arsenic Trioxide-Induced Apoptosis and Inhibition of Proliferation in AFP-Producing Gastric Cancer Cells | Q34575667 | ||
| ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis | Q34590025 | ||
| Stat3 activation of NF-{kappa}B p100 processing involves CBP/p300-mediated acetylation | Q34624443 | ||
| Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors | Q34666826 | ||
| STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers | Q34796500 | ||
| Combined Blockade of Src Kinase and Epidermal Growth Factor Receptor with Gemcitabine Overcomes STAT3-Mediated Resistance of Inhibition of Pancreatic Tumor Growth | Q34812100 | ||
| A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer | Q50767379 | ||
| Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. | Q52507969 | ||
| Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer | Q52949738 | ||
| Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis | Q53175859 | ||
| Phase III and submission failures: 2007–2010 | Q56564957 | ||
| Regulation of Interferon-α Responsiveness by the Duration of Janus Kinase Activity | Q57054942 | ||
| Electron Transfer between Cytochrome c and p66Shc Generates Reactive Oxygen Species that Trigger Mitochondrial Apoptosis | Q58454329 | ||
| Stat3/Socs3 Activation by IL-6 Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Cancer | Q60594558 | ||
| Pro-metastatic signaling by c-Met through RAC-1 and reactive oxygen species (ROS) | Q62030472 | ||
| Insulin-like growth factor-I (IGF-I) induces epidermal growth factor receptor transactivation and cell proliferation through reactive oxygen species | Q63561245 | ||
| c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability | Q74243929 | ||
| Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival | Q77387079 | ||
| Amplification of wild-type K-ras promotes growth of head and neck squamous cell carcinoma | Q78710253 | ||
| Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis | Q78836958 | ||
| Activation of signal transducer and activator of transcription 3 (Stat3) pathway in osteosarcoma cells and overexpression of phosphorylated-Stat3 correlates with poor prognosis. | Q39753786 | ||
| Activated Rac1 requires gp130 for Stat3 activation, cell proliferation and migration | Q39784105 | ||
| Ferritin heavy chain-mediated iron homeostasis and subsequent increased reactive oxygen species production are essential for epithelial-mesenchymal transition | Q39837172 | ||
| Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells | Q39843809 | ||
| Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding | Q39882795 | ||
| Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators | Q39933616 | ||
| Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor | Q40050607 | ||
| Design, synthesis, and studies of small molecule STAT3 inhibitors | Q40050988 | ||
| Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome | Q40098119 | ||
| Live cell imaging of interleukin-6-induced targeting of "transcription factor" STAT3 to sequestering endosomes in the cytoplasm. | Q40099327 | ||
| Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. | Q40105282 | ||
| The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation | Q40114178 | ||
| Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells | Q40166689 | ||
| Excessive nitric oxide attenuates leptin-mediated signal transducer and activator of transcription 3 activation | Q40209655 | ||
| STAT3 is required but not sufficient for EGF receptor-mediated migration and invasion of human prostate carcinoma cell lines | Q40262359 | ||
| Auranofin therapy in rheumatoid arthritis. | Q40265093 | ||
| Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3. | Q40309855 | ||
| Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways | Q40399370 | ||
| Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway | Q40410769 | ||
| Src-mediated tyrosine phosphorylation of p47phox in hyperoxia-induced activation of NADPH oxidase and generation of reactive oxygen species in lung endothelial cells | Q40445586 | ||
| Distinct mechanisms determine the patterns of differential activation of H-Ras, N-Ras, K-Ras 4B, and M-Ras by receptors for growth factors or antigen. | Q40540260 | ||
| Pyk2 amplifies epidermal growth factor and c-Src-induced Stat3 activation | Q40590054 | ||
| Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells | Q40658370 | ||
| Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis | Q40755904 | ||
| Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway | Q40776885 | ||
| STAT3 mediates the survival signal in oncogenicras-transfected intestinal epithelial cells | Q41003470 | ||
| Modeling synthetic lethality. | Q41404066 | ||
| Induction of cyclin D1 overexpression by activated ras. | Q41415663 | ||
| Overexpression of c-K-ras, c-N-ras and transforming growth factor beta co-segregate with tumorigenicity in morphologically transformed C3H 10T1/2 cell lines | Q41468970 | ||
| Reactive oxygen species as essential mediators of cell adhesion: the oxidative inhibition of a FAK tyrosine phosphatase is required for cell adhesion. | Q42048391 | ||
| Diverse Mechanisms of Somatic Structural Variations in Human Cancer Genomes | Q42061309 | ||
| Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma | Q42167271 | ||
| Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation | Q42425746 | ||
| Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents | Q42435827 | ||
| Interleukin-6-induced STAT3 transactivation and Ser727 phosphorylation involves Vav, Rac-1 and the kinase SEK-1/MKK-4 as signal transduction components | Q42485300 | ||
| Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor | Q42799161 | ||
| Activation of the JAK-STAT pathway by reactive oxygen species. | Q42823922 | ||
| Activation of signal transducer and activator of transcription 3 protects cardiomyocytes from hypoxia/reoxygenation-induced oxidative stress through the upregulation of manganese superoxide dismutase | Q43721242 | ||
| Reactive oxygen species as downstream mediators of angiogenic signaling by vascular endothelial growth factor receptor-2/KDR. | Q43806613 | ||
| Redox regulation of the G1 to S phase transition in the mouse embryo fibroblast cell cycle. | Q44427363 | ||
| High glucose augments the angiotensin II-induced activation of JAK2 in vascular smooth muscle cells via the polyol pathway. | Q44460146 | ||
| Membrane oxidative damage and apoptosis in cervical carcinoma cells of patients after radiation therapy | Q44483526 | ||
| Novel and recurrent STAT3 mutations in hyper-IgE syndrome patients from different ethnic groups. | Q44620077 | ||
| Cell membrane oxidative damage induced by gamma-radiation and apoptotic sensitivity | Q44782981 | ||
| The STAT3 isoforms alpha and beta have unique and specific functions | Q44800009 | ||
| Trial watch: Phase II failures: 2008-2010. | Q44967713 | ||
| STAT3 mediates cardioprotection against ischemia/reperfusion injury through metallothionein induction in the heart | Q45216534 | ||
| Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation | Q45223539 | ||
| EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment | Q45244872 | ||
| A role of STAT3 in Rho GTPase-regulated cell migration and proliferation | Q45261051 | ||
| Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial | Q45842857 | ||
| Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. | Q45930884 | ||
| pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantation. | Q45948514 | ||
| Multiple cysteine residues are implicated in Janus kinase 2-mediated catalysis | Q46872053 | ||
| Reactive oxygen species generation is involved in epidermal growth factor receptor transactivation through the transient oxidization of Src homology 2-containing tyrosine phosphatase in endothelin-1 signaling pathway in rat cardiac fibroblasts. | Q46878031 | ||
| Stability of c-K-ras amplification during progression in a patient with adenocarcinoma of the ovary | Q49280605 | ||
| Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor | Q28302317 | ||
| Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression | Q28346555 | ||
| Oxidative stress triggers STAT3 tyrosine phosphorylation and nuclear translocation in human lymphocytes | Q28377588 | ||
| Tyrosine kinase ETK/BMX is up-regulated in bladder cancer and predicts poor prognosis in patients with cystectomy | Q28477345 | ||
| Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway | Q28567314 | ||
| Evidence that IL-6-type cytokine signaling in cardiomyocytes is inhibited by oxidative stress: parthenolide targets JAK1 activation by generating ROS | Q28571807 | ||
| cAbl tyrosine kinase mediates reactive oxygen species- and caveolin-dependent AT1 receptor signaling in vascular smooth muscle: role in vascular hypertrophy | Q28582087 | ||
| Structure and function of a new STAT-induced STAT inhibitor | Q28584775 | ||
| Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase | Q28618942 | ||
| Requirement of serine phosphorylation for formation of STAT-promoter complexes | Q28637366 | ||
| Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6 | Q28637521 | ||
| STATs in cancer inflammation and immunity: a leading role for STAT3 | Q29547203 | ||
| GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors | Q29547630 | ||
| Stats: transcriptional control and biological impact | Q29547776 | ||
| Patterns of somatic mutation in human cancer genomes | Q29547841 | ||
| Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome | Q29614595 | ||
| Stat3 as an oncogene | Q29614606 | ||
| Requirement for generation of H2O2 for platelet-derived growth factor signal transduction | Q29615245 | ||
| Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo | Q29615579 | ||
| Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies | Q29615606 | ||
| Can the pharmaceutical industry reduce attrition rates? | Q29616077 | ||
| Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor | Q29616395 | ||
| Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation | Q29616396 | ||
| Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 | Q29617043 | ||
| Production of large amounts of hydrogen peroxide by human tumor cells | Q29617080 | ||
| STATs in oncogenesis | Q29617571 | ||
| BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis | Q29617585 | ||
| Association of reactive oxygen species levels and radioresistance in cancer stem cells | Q29617812 | ||
| Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability | Q29618122 | ||
| Screening for epidermal growth factor receptor mutations in lung cancer | Q29619696 | ||
| Diverse somatic mutation patterns and pathway alterations in human cancers | Q29619825 | ||
| Phosphatidylinositol-3-OH kinase as a direct target of Ras | Q29620177 | ||
| Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) | Q29620605 | ||
| SH2 domains prevent tyrosine dephosphorylation of the EGF receptor: identification of Tyr992 as the high-affinity binding site for SH2 domains of phospholipase C gamma | Q30195496 | ||
| An EGF receptor/Ral-GTPase signaling cascade regulates c-Src activity and substrate specificity | Q30449907 | ||
| Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein | Q30453603 | ||
| S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death | Q30843579 | ||
| Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction | Q30976301 | ||
| Cellular thiols and reactive oxygen species in drug-induced apoptosis | Q31725534 | ||
| A Ras homologue member I directly inhibits signal transducers and activators of transcription 3 translocation and activity in human breast and ovarian cancer cells | Q33220842 | ||
| Stattic: a small-molecule inhibitor of STAT3 activation and dimerization | Q33264035 | ||
| Synthetic lethal screen identification of chemosensitizer loci in cancer cells | Q33281866 | ||
| Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity | Q33282964 | ||
| Stat3 isoforms, alpha and beta, demonstrate distinct intracellular dynamics with prolonged nuclear retention of Stat3beta mapping to its unique C-terminal end. | Q33298860 | ||
| A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis | Q33399980 | ||
| U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis | Q33400986 | ||
| Disruption of astrocyte STAT3 signaling decreases mitochondrial function and increases oxidative stress in vitro | Q33540157 | ||
| The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors | Q33613105 | ||
| A Cell-permeable Stat3 SH2 Domain Mimetic Inhibits Stat3 Activation and Induces Antitumor Cell Effects in Vitro | Q33679564 | ||
| Human RAS superfamily proteins and related GTPases | Q33689727 | ||
| STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress | Q33733773 | ||
| Identification of a Stat3-dependent transcription regulatory network involved in metastatic progression. | Q33740488 | ||
| Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3 | Q33780701 | ||
| Expression of p-STAT3 in human gastric carcinoma: significant correlation in tumour invasion and prognosis | Q79488473 | ||
| Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial | Q80178480 | ||
| Differential expression of STAT5 and Bcl-xL, and high expression of Neu and STAT3 in non-small-cell lung carcinoma | Q80228054 | ||
| The state of innovation in drug development | Q80509427 | ||
| Auranofin blocks interleukin-6 signalling by inhibiting phosphorylation of JAK1 and STAT3 | Q80653943 | ||
| Inverse association between Raf Kinase Inhibitory Protein and signal transducers and activators of transcription 3 expression in gastric adenocarcinoma patients: implications for clinical outcome | Q81286559 | ||
| Activation of the signal transducers and activators of the transcription 3 pathway in alveolar epithelial cells induces inflammation and adenocarcinomas in mouse lung | Q81310114 | ||
| Destructive pulmonary staphylococcal infection in a boy with hyper-IgE syndrome: a novel mutation in the signal transducer and activator of transcription 3 (STAT3) gene (p.Y657S) | Q82605242 | ||
| Targeting STAT3 in cancer: how successful are we? | Q82824786 | ||
| An adolescent with marked hyperimmuno-globulinemia E showing minimal change nephrotic syndrome and a STAT3 gene mutation | Q83681689 | ||
| Stat3 promotes directional cell migration by regulating Rac1 activity via its activator betaPIX | Q84793774 | ||
| Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota | Q34828123 | ||
| Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth | Q34922227 | ||
| Design and discovery of small molecules targeting raf-1 kinase | Q34946014 | ||
| The R(h)oads to Stat3: Stat3 activation by the Rho GTPases | Q35086590 | ||
| Radical causes of cancer. | Q35097371 | ||
| Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas | Q35102345 | ||
| A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes | Q35282743 | ||
| Mitochondrial-targeted Signal transducer and activator of transcription 3 (STAT3) protects against ischemia-induced changes in the electron transport chain and the generation of reactive oxygen species | Q35313598 | ||
| The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24– stem cell–like breast cancer cells in human tumors | Q35572396 | ||
| A nuclear protein tyrosine phosphatase is required for the inactivation of Stat1. | Q35618119 | ||
| Maintenance of tumor initiating cells of defined genetic composition by nucleostemin | Q35650954 | ||
| Nitric oxide and thiol redox regulation of Janus kinase activity | Q35669297 | ||
| In vitro activation of Stat3 by epidermal growth factor receptor kinase | Q35924599 | ||
| Targeting the Interleukin-6/Jak/Stat Pathway in Human Malignancies | Q35925127 | ||
| Non-Hodgkin's lymphoma in Job's syndrome: a case report and literature review | Q35994876 | ||
| Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity | Q36020891 | ||
| Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome | Q36028793 | ||
| Antitumor activity of a novel STAT3 inhibitor and redox modulator in non-small cell lung cancer cells | Q36081620 | ||
| STAT3 Mediates Resistance to MEK Inhibitor through MicroRNA miR-17 | Q36083385 | ||
| Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. | Q36243533 | ||
| Global synthetic-lethality analysis and yeast functional profiling | Q36323084 | ||
| Activated Ras prevents downregulation of Bcl-X(L) triggered by detachment from the extracellular matrix. A mechanism of Ras-induced resistance to anoikis in intestinal epithelial cells | Q36328354 | ||
| Ras mediates effector pathways responsible for pre-B cell survival, which is essential for the developmental progression to the late pre-B cell stage | Q36368736 | ||
| Ras transformation results in an elevated level of cyclin D1 and acceleration of G1 progression in NIH 3T3 cells | Q36552538 | ||
| Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation | Q36556010 | ||
| EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104 | Q36594155 | ||
| NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations | Q36645788 | ||
| Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function | Q36662693 | ||
| Constitutive activation of STAT3 and STAT5 is present in the majority of nasopharyngeal carcinoma and correlates with better prognosis | Q36670981 | ||
| Stat3 promotes metastatic progression of prostate cancer. | Q36691140 | ||
| Small molecule inhibitors of Stat3 signaling pathway. | Q36737720 | ||
| Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells | Q36742242 | ||
| Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3 | Q36742247 | ||
| Requirement of histone deacetylase1 (HDAC1) in signal transducer and activator of transcription 3 (STAT3) nucleocytoplasmic distribution | Q36798717 | ||
| Molecular basis for sunitinib efficacy and future clinical development | Q36906667 | ||
| Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression | Q36945006 | ||
| The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. | Q37020840 | ||
| Specific fate decisions in adult hepatic progenitor cells driven by MET and EGFR signaling | Q37098168 | ||
| Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylation | Q37113677 | ||
| Interruption of RNA processing machinery by a small compound, 1-[(4-chlorophenyl)methyl]-1H-indole-3-carboxaldehyde (oncrasin-1). | Q37121568 | ||
| S-glutathionylation impairs signal transducer and activator of transcription 3 activation and signaling. | Q37125937 | ||
| The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling. | Q37244392 | ||
| Is the focus moving toward a combination of targeted drugs? | Q37337409 | ||
| Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinoma. | Q37345331 | ||
| Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro | Q37385294 | ||
| Redox state is a central modulator of the balance between self-renewal and differentiation in a dividing glial precursor cell | Q37397172 | ||
| STAT3 inhibition of gluconeogenesis is downregulated by SirT1 | Q37466250 | ||
| Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials | Q37600130 | ||
| Diffuse Large B Cell Lymphoma in Hyper-IgE Syndrome Due To STAT3 Mutation | Q37791014 | ||
| Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein. | Q38014908 | ||
| Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis | Q38290076 | ||
| Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target | Q38326252 | ||
| Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. | Q38934630 | ||
| Constitutively Activated Jak-STAT Pathway in T Cells Transformed with HTLV-I | Q39250459 | ||
| Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation | Q39297840 | ||
| Let-7 expression is a significant determinant of response to chemotherapy through the regulation of IL-6/STAT3 pathway in esophageal squamous cell carcinoma | Q39305337 | ||
| JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation | Q39328532 | ||
| Gold(I) carbene complexes causing thioredoxin 1 and thioredoxin 2 oxidation as potential anticancer agents | Q39343564 | ||
| Interleukin-11 links oxidative stress and compensatory proliferation. | Q39410701 | ||
| STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. | Q39540918 | ||
| Nonreceptor Tyrosine Kinase BMX Maintains Self-Renewal and Tumorigenic Potential of Glioblastoma Stem Cells by Activating STAT3 | Q39560754 | ||
| Suppression of Stat3 activity sensitizes gefitinib-resistant non small cell lung cancer cells | Q39575899 | ||
| Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. | Q39675800 | ||
| Clinical value of signal transducers and activators of transcription 3 (STAT3) gene expression in human osteosarcoma | Q39693331 | ||
| Rho family GTPases are required for activation of Jak/STAT signaling by G protein-coupled receptors | Q39700439 | ||
| Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten | Q39730145 | ||
| INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support | Q39752237 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P304 | page(s) | 494-525 | |
| P577 | publication date | 2014-03-06 | |
| P1433 | published in | Cancers | Q27722963 |
| P1476 | title | Genetic Interactions of STAT3 and Anticancer Drug Development | |
| P478 | volume | 6 |
| Q55364953 | Blocking of the EGFR-STAT3 signaling pathway through afatinib treatment inhibited the intrahepatic cholangiocarcinoma. |
| Q35815736 | Doxorubicin resistance in breast cancer is driven by light at night-induced disruption of the circadian melatonin signal |
| Q38957393 | Ficus carica latex prevents invasion through induction of let-7d expression in GBM cell lines |
| Q92859346 | Functional interplay between NF-κB-inducing kinase and c-Abl kinases limits response to Aurora inhibitors in multiple myeloma |
| Q101038958 | Genome-wide CRISPR screen identifies LGALS2 as an oxidative stress-responsive gene with an inhibitory function on colon tumor growth |
| Q91649695 | Inhibition of STAT3 signaling induces apoptosis and suppresses growth of lung cancer: good and bad |
| Q42177413 | Metabolic flux-driven sialylation alters internalization, recycling, and drug sensitivity of the epidermal growth factor receptor (EGFR) in SW1990 pancreatic cancer cells. |
| Q26824536 | Predictive biomarkers in precision medicine and drug development against lung cancer |
| Q36398735 | RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies |
| Q35051599 | WHI-P154 enhances the chemotherapeutic effect of anticancer agents in ABCG2-overexpressing cells. |
Search more.